RespireRx Pharmaceuticals Inc CEO Arnold Lippa joined Steve Darling from Proactive to unveil exciting developments within the company. Lippa shared the groundbreaking news that RespireRx’s lead GABAA receptor potentiator, KRM-II-81, has ascended to the next phase of evaluation within the esteemed NIH HEAL Initiative® Preclinical Screening Platform for Pain program.

The NIH HEAL Initiative, an integral component in combatting the national opioid public health crisis, stands as a collaborative and resolute effort aimed at accelerating scientific solutions.

Launched in April 2018, this initiative is dedicated to advancing prevention and treatment strategies for opioid misuse and addiction, while concurrently enhancing pain management protocols. Lippa elaborated on the significant progress made with KRM-II-81, citing emerging data that showcased its efficacy in mitigating pain-like behaviors in rats. Remarkably, these effects were observed at doses demonstrating minimal or no detectable side effects, underscoring the compound’s potential for therapeutic success.

These promising results were witnessed across both male and female rats, across two distinct measures, including models of post-incision pain and spinal nerve ligation-induced persistent neuropathic pain.

This latest research builds upon prior observations made by RespireRx Pharmaceuticals Inc and other laboratories, affirming KRM-II-81’s effectiveness in alleviating acute, chronic, and neuropathic pain across various experimental models. Importantly, these benefits were achieved without the development of tolerance or sedation, highlighting the compound’s favorable safety profile and therapeutic potential. As a result of these compelling findings, KRM-II-81 has progressed within the NIH PSPP program, where it will undergo further evaluation across additional disease-specific pain models. With promising clinical validation on the horizon, RespireRx Pharmaceuticals Inc firmly believes that KRM-II-81 holds the potential to emerge as a groundbreaking medication not only for pain management but also for the treatment of epilepsy and other neuropsychiatric disorders.

This remarkable advancement underscores the company’s commitment to pioneering innovative solutions that address critical medical needs and improve patient outcomes.